FDA delays action date for Requip XL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA needs additional time to review GlaxoSmithKline's newly submitted data on Parkinson's disease candidate Requip XL (ropinirole extended-release), pushing the user fee date back into the second quarter. GSK submitted data after receiving an "approvable" letter concerning proposed labeling and expected a decision in the first quarter. The firm hopes to switch patients to the extended-release formulation, which is already approved in immediate-release form for Parkinson's and restless legs syndrome, ahead of anticipated generic competition in May...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.